193 related articles for article (PubMed ID: 37473593)
41. Pattern of thalamic nuclei atrophy in early relapse-onset multiple sclerosis.
Levy S; Sandry J; Beck ES; Brandstadter R; Katz Sand I; Sumowski JF
Mult Scler Relat Disord; 2022 Nov; 67():104083. PubMed ID: 35940020
[TBL] [Abstract][Full Text] [Related]
42. The glymphatic system as a potential biomarker and therapeutic target in secondary progressive multiple sclerosis.
Tomizawa Y; Hagiwara A; Hoshino Y; Nakaya M; Kamagata K; Cossu D; Yokoyama K; Aoki S; Hattori N
Mult Scler Relat Disord; 2024 Mar; 83():105437. PubMed ID: 38244527
[TBL] [Abstract][Full Text] [Related]
43. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Kim G; Chu R; Yousuf F; Tauhid S; Stazzone L; Houtchens MK; Stankiewicz JM; Severson C; Kimbrough D; Quintana FJ; Chitnis T; Weiner HL; Healy BC; Bakshi R
Int J Neurosci; 2017 Nov; 127(11):971-980. PubMed ID: 28100092
[TBL] [Abstract][Full Text] [Related]
44. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up.
Strautmane S; Balodis A; Teivane A; Grabovska D; Naudins E; Urbanovics D; Fisermans E; Mednieks J; Flintere-Flinte A; Priede Z; Millers A; Zolovs M
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374286
[No Abstract] [Full Text] [Related]
45. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
[TBL] [Abstract][Full Text] [Related]
46. Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
Jakimovski D; Ramanathan M; Weinstock-Guttman B; Bergsland N; Ramasamay DP; Carl E; Dwyer MG; Zivadinov R
Mult Scler; 2020 Mar; 26(3):322-332. PubMed ID: 30755085
[TBL] [Abstract][Full Text] [Related]
47. Progression of regional grey matter atrophy in multiple sclerosis.
Eshaghi A; Marinescu RV; Young AL; Firth NC; Prados F; Jorge Cardoso M; Tur C; De Angelis F; Cawley N; Brownlee WJ; De Stefano N; Laura Stromillo M; Battaglini M; Ruggieri S; Gasperini C; Filippi M; Rocca MA; Rovira A; Sastre-Garriga J; Geurts JJG; Vrenken H; Wottschel V; Leurs CE; Uitdehaag B; Pirpamer L; Enzinger C; Ourselin S; Gandini Wheeler-Kingshott CA; Chard D; Thompson AJ; Barkhof F; Alexander DC; Ciccarelli O
Brain; 2018 Jun; 141(6):1665-1677. PubMed ID: 29741648
[TBL] [Abstract][Full Text] [Related]
48. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
[TBL] [Abstract][Full Text] [Related]
49. Network Damage Predicts Clinical Worsening in Multiple Sclerosis: A 6.4-Year Study.
Rocca MA; Valsasina P; Meani A; Pagani E; Cordani C; Cervellin C; Filippi M
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34021055
[TBL] [Abstract][Full Text] [Related]
50. Olfactory Dysfunction Reflects Disease Progression in Japanese Patients with Multiple Sclerosis.
Okada K; Kakeda S; Tahara M
Intern Med; 2022 Nov; 61(21):3181-3187. PubMed ID: 35400704
[TBL] [Abstract][Full Text] [Related]
51. Magnetic resonance fingerprinting in multiple sclerosis.
Ontaneda D; Gulani V; Deshmane A; Shah A; Guruprakash DK; Jiang Y; Ma D; Fisher E; Rudick RA; Raza P; Kilbane M; Cohen JA; Sakaie K; Lowe MJ; Griswold MA; Nakamura K
Mult Scler Relat Disord; 2023 Nov; 79():105024. PubMed ID: 37783196
[TBL] [Abstract][Full Text] [Related]
52. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.
Pontillo G; Cocozza S; Lanzillo R; Russo C; Stasi MD; Paolella C; Vola EA; Criscuolo C; Borrelli P; Palma G; Tedeschi E; Morra VB; Elefante A; Brunetti A
AJNR Am J Neuroradiol; 2019 Jan; 40(1):99-106. PubMed ID: 30573464
[TBL] [Abstract][Full Text] [Related]
53. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
[TBL] [Abstract][Full Text] [Related]
54. Attention and processing speed performance in multiple sclerosis is mostly related to thalamic volume.
Bisecco A; Stamenova S; Caiazzo G; d'Ambrosio A; Sacco R; Docimo R; Esposito S; Cirillo M; Esposito F; Bonavita S; Tedeschi G; Gallo A
Brain Imaging Behav; 2018 Feb; 12(1):20-28. PubMed ID: 28083844
[TBL] [Abstract][Full Text] [Related]
55. Subtyping relapsing-remitting multiple sclerosis using structural MRI.
Zhuo Z; Li Y; Duan Y; Cao G; Zheng F; Ding J; Tian D; Wang X; Wang J; Zhang X; Li K; Zhou F; Huang M; Li Y; Li H; Zeng C; Zhang N; Sun J; Yu C; Han X; Haller S; Barkhof F; Shi F; Liu Y
J Neurol; 2021 May; 268(5):1808-1817. PubMed ID: 33387013
[TBL] [Abstract][Full Text] [Related]
56. Focal cortical thinning in patients with stable relapsing-remitting multiple sclerosis: cross-sectional-based novel estimation of gray matter kinetics.
Orbach L; Menascu S; Hoffmann C; Miron S; Achiron A
Neuroradiology; 2018 Feb; 60(2):179-187. PubMed ID: 29285552
[TBL] [Abstract][Full Text] [Related]
57. The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
Bonacchi R; Meani A; Pagani E; Marchesi O; Filippi M; Rocca MA
J Neurol; 2022 Jul; 269(7):3841-3857. PubMed ID: 35230471
[TBL] [Abstract][Full Text] [Related]
58. Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Arnold DL; Piani-Meier D; Bar-Or A; Benedict RH; Cree BA; Giovannoni G; Gold R; Vermersch P; Arnould S; Dahlke F; Hach T; Ritter S; Karlsson G; Kappos L; Fox RJ;
Mult Scler; 2022 Sep; 28(10):1526-1540. PubMed ID: 35261318
[TBL] [Abstract][Full Text] [Related]
59. The role of endogenous antiradical protective system in multiple sclerosis.
Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
[TBL] [Abstract][Full Text] [Related]
60. MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction.
Anderson VM; Fisniku LK; Altmann DR; Thompson AJ; Miller DH
Mult Scler; 2009 Jul; 15(7):811-7. PubMed ID: 19465449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
